Pharmacokinetics and population pharmacodynamic analysis of lanreotide AutogelCENDROS, Joseph M; PERAIRE, Concepcion; FERNANDEZ-TROCONIZ, Inaki et al.Metabolism, clinical and experimental. 2005, Vol 54, Num 10, pp 1276-1281, issn 0026-0495, 6 p.Article

In Vitro Metabolism of Irosustat, a Novel Steroid Sulfatase Inhibitor: Interspecies Comparison, Metabolite Identification, and Metabolic Enzyme IdentificationVENTURA, Veronica; SOLA, Josep; CELMA, Carles et al.Drug metabolism and disposition. 2011, Vol 39, Num 7, pp 1235-1246, issn 0090-9556, 12 p.Article

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumoursTROCONIZ, Inaki F; GARRIDO, Maria J; SEGURA, Cristina et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 6, pp 727-735, issn 0344-5704, 9 p.Article

Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiencyTOMLINSON, Brian; THOMAS, Neil G; LAN, Irene W et al.Clinical pharmacokinetics. 2006, Vol 45, Num 10, pp 1003-1011, issn 0312-5963, 9 p.Article

A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancerCOOMBES, R. Charles; CARDOSO, Fatima; ISAMBERT, Nicolas et al.Breast cancer research and treatment. 2013, Vol 140, Num 1, pp 73-82, issn 0167-6806, 10 p.Article

Population Pharmacokinetics of High-Dose Methotrexate After Intravenous Administration in Pediatric Patients With OsteosarcomaCOLOM, Helena; FARRE, Rosa; SOY, Dolors et al.Therapeutic drug monitoring. 2009, Vol 31, Num 1, pp 76-85, issn 0163-4356, 10 p.Article